These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8394544)

  • 1. Fish oil and antioxidant supplements reduce erythropoietin requirement in haemodialysis patients.
    Nordkild PK; Graff J; Jørgensen HE; Fugleberg S
    Nephrol Dial Transplant; 1993; 8(6):569. PubMed ID: 8394544
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant human erythropoietin in anaemic patients on haemodialysis.
    Bommer J; Müller-Bühl E; Ritz E; Eifert J
    Lancet; 1987 Feb; 1(8529):392. PubMed ID: 2880204
    [No Abstract]   [Full Text] [Related]  

  • 3. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 4. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
    BMJ; 1990 Mar; 300(6724):573-8. PubMed ID: 2108751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of withdrawing erythropoietin.
    Taylor JE; Henderson IS; Mactier RA; Stewart WK
    BMJ; 1991 Feb; 302(6771):272-3. PubMed ID: 1998794
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of renal anemia with recombinant human erythropoietin].
    Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A
    Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vital indication for erythropoietin in a chronic haemodialysis patient. A case report.
    Nielsen OJ; Thaysen JH
    Dan Med Bull; 1989 Dec; 36(6):590-2. PubMed ID: 2612227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
    de Fijter CW; Popp-Snijders C; Oe LP; Tran DD; van der Meulen J; Donker AJ
    Haematologica; 1995; 80(4):332-4. PubMed ID: 7590502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human recombinant erythropoietin in anaemic patients on maintenance haemodialysis. Secondary effects of the increase of haemoglobin.
    Zehnder C; Glück Z; Descoeudres C; Uehlinger DE; Blumberg A
    Nephrol Dial Transplant; 1988; 3(5):657-60. PubMed ID: 3146724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal erythropoietin.
    Frenken LA; Coppens PJ; Tiggeler RG; Koene RA
    Lancet; 1988 Dec 24-31; 2(8626-8627):1495. PubMed ID: 2904611
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dosage of erythropoietin in children treated with hemodialysis and continuous ambulatory peritoneal dialysis].
    Sieniawska M; Roszkowska-Blaim M
    Pediatr Pol; 1995 Dec; 70(12):1023-8. PubMed ID: 8649941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation.
    Trebble TM; Wootton SA; Miles EA; Mullee M; Arden NK; Ballinger AB; Stroud MA; Burdge GC; Calder PC
    Am J Clin Nutr; 2003 Sep; 78(3):376-82. PubMed ID: 12936918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
    Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
    Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis.
    Shirazian S; Grant C; Miller I; Fishbane S
    Semin Dial; 2013; 26(5):534-6. PubMed ID: 23763675
    [No Abstract]   [Full Text] [Related]  

  • 15. Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha.
    Walker R; Pussell BA;
    Nephrology (Carlton); 2009 Oct; 14(7):689-95. PubMed ID: 19796029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fish oil attenuates adrenergic overactivity without altering glucose metabolism during an oral glucose load in haemodialysis patients.
    Delarue J; Guillodo MP; Guillerm S; Elbaz A; Marty Y; Clèdes J
    Br J Nutr; 2008 May; 99(5):1041-7. PubMed ID: 17977474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodialysis efficiency after long-term treatment with recombinant human erythropoietin.
    Casati S; Campise M; Crepaldi M; Lobo J; Graziani G; Ponticelli C
    Nephrol Dial Transplant; 1989; 4(8):718-20. PubMed ID: 2510080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of subcutaneous recombinant human erythropoietin (r-Hu EPO) in CAPD patients with renal anaemia.
    Janicka L; Ksiazek A; Baranowicz I; Mierzicki P
    Ann Univ Mariae Curie Sklodowska Med; 1994; 48 Suppl 3():67-77. PubMed ID: 8192534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythropoietin.
    Winearls CG
    Nephrol Dial Transplant; 1989; 4(5):323-6. PubMed ID: 2505180
    [No Abstract]   [Full Text] [Related]  

  • 20. Associations of fish oil and vitamin B and E supplementation with cardiovascular outcomes and mortality in people receiving haemodialysis: a review.
    Bessell E; Jose MD; McKercher C
    BMC Nephrol; 2015 Aug; 16():143. PubMed ID: 26283325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.